China Medical & HealthCare Group Limited provided group earnings guidance for the five months ended 31 May 2023. For the five months, the Group is expected to record a loss attributable to the Shareholders for the five months ended 31 May 2023 which represents an approximately 87% to 97% decrease in loss as compared with (i) the loss for the corresponding period in 2022; and (ii) the loss for the six months ended 30 June 2022 respectively. This was mainly due to (i) the increase in revenue from operations of the healthcare division; and (ii) the decrease in cost of medical consumables but was partially off-set by (iii) the increase in cost of pharmaceutical and medicine, amid the relaxation of epidemic preventive measures and the resumption of economic and social activities in the People's Republic of China.